Related by context. All words. (Click for frequent words.) 79 Phase 2b Clinical Trial 78 Phase 2b Trial 78 Phase 2a Clinical Trial 77 Oral Fingolimod 76 Treated Patients 76 Study Evaluating 76 Meets Primary Endpoint 76 Prolongs Survival 76 Clinical Trial Evaluating 75 Patient Enrollment 75 First Patient Enrolled 75 Drug Candidate 75 Phase IIb Clinical Trial 75 Successfully Completes Phase 75 Phase IIb Trial 74 Clinical Trial Results 74 Phase 2b Study 74 Adjuvant Treatment 74 FDA Approvals 74 Lung Cancer Trial 74 Phase III Trial 74 Preclinical Data 74 Phase 2a Trial 74 See CLINICAL PHARMACOLOGY 74 Initiates Clinical Trial 74 Novel Inhibitor 74 Parathyroid Hormone 74 HDAC Inhibitor 73 Neoadjuvant Chemotherapy 73 Demonstrates Significant 73 Pooled Analysis 73 Completes Patient Enrollment 73 Adjunctive Therapy 73 Adjuvant Chemotherapy 73 Phase IIa Clinical Trial 73 Plaque Psoriasis 73 Protease Inhibitor 73 Clinical Trial Data 73 Antiviral Activity 73 Tyrosine Kinase Inhibitor 73 Phase 1b Clinical Trial 73 First Patient Dosed 73 Initiate Phase 73 NDA Submission 73 II Clinical Trial 73 Combination Treatment 73 Systemic Sclerosis 73 Completes Enrollment 73 Trial Evaluating 73 Biomarker Study 72 Schizophrenia Treatment 72 Phase III Clinical Trial 72 Double Blind Placebo 72 IND Filing 72 Dose Ranging Study 72 J Clin 72 Kinase Inhibitor 72 Investigational Treatment 72 Patients Treated With 72 Mouse Model 72 Novel Compound 72 lexidronam injection 72 Preclinical Study 72 ALN HPN 72 Pharmacokinetic Study 72 Relapsing Multiple Sclerosis 72 Randomized Phase 72 Therapeutic Antibody 72 Novel Oral 72 Hormone Refractory Prostate Cancer 71 Hormone Receptor Positive 71 Study Demonstrates 71 Progenitor Cells 71 Randomized Double Blind 71 Antitumor Activity 71 Anti Tumor Activity 71 Initiates Clinical 71 Pivotal Trial 71 Placebo Controlled Trial 71 Presents Preclinical Data 71 Antiviral Therapy 71 Anti Tumor 71 Sirolimus Eluting Stent 71 Controlled Study 71 Randomized Study 71 Demonstrates Positive 71 Metastatic Prostate Cancer 71 Heart Failure Patients 71 Receives Orphan Drug Designation 71 Pivotal Phase III 71 Controlled Trial 71 Severe Sepsis 71 TO AVOID PREGNANCY WHILE 71 Pivotal Study 71 Dose Escalation 71 JAK2 Inhibitor 71 Clinical Evaluation 71 Begins Dosing 71 Nicotine Vaccine 71 Pivotal Phase 71 HCV Protease Inhibitor 71 Improves Outcomes 71 Clinical Outcome 71 Single Dose 70 Polymerase Inhibitor 70 Orthop Surg 70 Randomized Clinical Trial 70 Castration Resistant Prostate Cancer 70 Prospective Multicenter 70 Tezampanel 70 Diabetic Foot Ulcer 70 Prospective Randomized 70 Crit Rev 70 Diabetic Neuropathy 70 Patients Receiving 70 Advanced Melanoma 70 Previously Treated 70 Metastatic Melanoma 70 Bosutinib 70 Chronic Hepatitis C 70 Granted Orphan Drug 70 Minimally Invasive Treatment 70 Potent Inhibitor 70 IND Application 70 Acute Ischemic Stroke 70 Treatment Naïve 70 Anticancer Drug 70 Demonstrates Efficacy 70 Phase III Pivotal 70 Proc Am Soc 70 Myoblast 70 Investigational Drug 70 Poster Presentations 70 Hsp# Inhibitor 70 Initiates Phase II 70 Demonstrates Potent 70 Confirmatory Phase 70 Presents Positive 70 Novel Therapeutic 70 Improves Survival 70 metastatic malignant 70 Clostridium difficile Infection 70 Pharmacokinetics PK 70 Patient Enrolment 70 Phase III Trials 70 Shows Promise Against 70 Left Ventricular 70 Allogeneic 70 Immunotherapeutic 70 Commences Phase 70 Files IND 70 Metastatic Renal Cell Carcinoma 70 Submits NDA 70 Lupus Drug 70 Collaborators Present 70 Investigational Compound 69 Pivotal Clinical Trial 69 Initiates Phase III 69 Initiated Phase 69 #-# Full Text 69 J Am Coll 69 Ozarelix 69 Prognostic Value 69 Percutaneous Tibial Nerve Stimulation 69 Anticancer Agent 69 Shows Promising 69 THERAPEUTICS 69 fosbretabulin 69 Dose Ranging 69 Fungal Infections 69 PDUFA Date 69 Nephrol 69 Poster Discussion 69 Cutaneous T 69 Shows Efficacy 69 Metabolic Efficiency 69 Combination REOLYSIN R 69 Non Invasive Treatment 69 Patients Treated 69 RNAi Therapeutic 69 Systemic Delivery 69 Eur J 69 Investigational Oral 69 JAK Inhibitor 69 First Patient Treated 69 Elderly Patients 69 Antiangiogenic 69 Initiates Enrollment 69 Cinacalcet 69 Vascular Disrupting Agent 69 Aflibercept 69 Achieves Primary Endpoint 69 Glufosfamide 69 Preclinical Models 69 Valve Replacement 69 FASEB J. 69 Telaprevir VX 69 Ranolazine 69 Meta Analysis 69 Placebo Controlled Study 69 Antigen Specific 69 FDA APPROVES 69 Autologous Stem Cell Transplantation 69 Disease Modifying 69 Pivotal Trials 69 Long Term Efficacy 69 Immunomedics Announces 69 Attenuates 69 Plus Ribavirin 69 Slow Progression 69 Myelodysplastic Syndrome MDS 69 Advanced Renal Cell 69 Treating Chronic 69 Oral Formulation 69 Refractory Angina 69 Demonstrate Significant 69 Immunomodulatory 69 Demonstrated Significant 69 Anticancer Activity 69 Initiates Phase 2b 69 Patients Suffering 69 Is Well Tolerated 69 Mouse Models 68 Randomized Double blind 68 PHASE III 68 Cardiotoxicity 68 Placebo Controlled 68 Phase 1b clinical trials 68 Demonstrates Sustained 68 Orally Active 68 CCX# B 68 Curr Opin 68 Renal Cancer 68 Initiate Clinical Trial 68 Present Preclinical Data 68 Mg Usa 68 Diabetic Nephropathy 68 Suppl. 68 Peripheral Arterial 68 Interferon Gamma 68 Relapsing Remitting Multiple Sclerosis 68 Bone Metastases 68 Therapeutic Vaccine 68 Inflammatory Markers 68 familial amyloidotic polyneuropathy FAP 68 Milestone Payment 68 Peginterferon Alfa 2a 68 Remission Maintenance 68 Monoclonal Antibody 68 beta 1a 68 Prognostic Significance 68 Hematological Malignancies 68 dasatinib Sprycel ® 68 Myelodysplastic Syndromes 68 Inflammatory Arthritis 68 Randomized Clinical Trials 68 Mimetics 68 Relapsed Refractory 68 Novel Mechanism 68 Investigational Agent 68 Multiple Ascending Dose 68 Kidney Transplant Patients 68 Renal Function 68 Phase III Clinical Trials 68 abstr 68 Secondary Hyperparathyroidism 68 VentiRx Pharmaceuticals 68 Pulmonary Arterial Hypertension 68 Randomized Controlled 68 Ocrelizumab 68 Newly Diagnosed Multiple Myeloma 68 Inhaled Corticosteroids 68 Inflammatory Disease 68 Treatment Reduces 68 Lupus Nephritis 68 Initiate Phase III 68 Aurora Kinase 68 Gastric Cancer 68 Interferon Beta 68 Embolic Protection 68 By JENNIFER LEARN 68 Peginterferon 68 Receptor Agonist 68 Osteoporosis Treatment 68 Orthostatic Hypotension 68 Hypertensive Patients 68 AAG geldanamycin analog 68 Skeletal Muscle 68 Randomized Evaluation 68 Vaccine Adjuvant 68 Stent Restenosis 68 Eluting Stent 68 Shows Statistically Significant 68 alfa 2a 68 Renal Cell Carcinoma 68 Endocrinol 68 Improve Survival 68 Ridaforolimus 68 Randomized Trials 68 Arch Neurol 68 Central Retinal Vein 68 PEG IFN 68 Laryngeal Cancer 68 Hemodialysis Patients 68 Interferon beta 1a 68 Clinical Outcomes 68 drugs davunetide intranasal 68 Oral Calcitonin 68 Lung Cancer Drug 68 ST Segment Elevation 68 IN PATIENTS WITH 68 Confirms Efficacy 68 Mycophenolate Mofetil 68 Oral Mucositis 68 Psoriasis Drug 68 Hepatitis C Treatment 68 Rheumatoid Arthritis Patients 68 Obstet Gynecol 68 Elagolix 68 Angiotensin Converting Enzyme 68 Protease Inhibitors 68 Phase #b/#a clinical 68 vapreotide acetate 68 Significantly Reduces 68 Early Relapsing Multiple 68 Bepreve TM 68 J Am Soc 68 Knee Osteoarthritis 68 Gout Drug 68 Replacement Therapy 67 Severe Asthma 67 Acute Decompensated Heart Failure 67 Non Alcoholic Steatohepatitis 67 Podium Presentation 67 Histone Deacetylase 67 Inhalation Solution 67 GW# [003] 67 Mol Cell 67 AVONEX ® 67 Skin Lesions 67 Files Investigational 67 Therapeutic Targets 67 dependent kinase inhibitor 67 Complicated Skin 67 Subgroup Analysis 67 Zorbtive TM 67 Personalized Immunotherapy 67 Proven Effective 67 Clin Oncol 67 Lubiprostone 67 ara C 67 Randomized Controlled Trials 67 Hematological 67 Non Responders 67 Drug Prevents 67 Child Adolesc Psychiatry 67 transthyretin TTR mediated amyloidosis 67 Late Breaker 67 Symptom Relief 67 Protein Expression 67 Pegylated Liposomal Doxorubicin 67 Cell Transplant 67 Patients Undergoing 67 Critical Limb Ischemia CLI 67 Migraine Drug 67 Nat Clin Pract 67 ANN INTERN MED 67 cetuximab Erbitux R 67 Neurol 67 IL# PE#QQR 67 myelodysplastic myeloproliferative diseases 67 Glatiramer Acetate 67 Radioimmunotherapy 67 Infarct 67 Left Ventricular Hypertrophy 67 Catheter Ablation 67 pan histone deacetylase 67 Double Blind Randomized 67 Cardiol 67 Significantly Improves 67 Subtypes 67 HER2 Positive 67 TRANSFORMS 67 Lipid Lowering 67 Chemoradiation 67 Left Ventricular Dysfunction 67 Renal Insufficiency 67 ISTODAX ® 67 Antiplatelet 67 Newly Diagnosed 67 Contrast Agents 67 Safinamide 67 MEK Inhibitor 67 Hepatitis C Genotype 67 Novel Treatments 67 Anticancer Agents 67 Radiation Induced 67 Randomized Double Blind Placebo 67 Appears Safe 67 Myelofibrosis 67 Nebulized 67 Chronic Heart Failure 67 Brentuximab Vedotin SGN 67 novel histone deacetylase 67 Corneal Transplant 67 Pharmaceuticals Initiates 67 Infected Patients 67 Novel Antibiotic 67 Prophylactic Treatment 67 Cognitive Impairment 67 Spectrum Pharmaceuticals Announces 67 Topline Results 67 Predict Risk 67 Medoxomil 67 Multicenter Phase 67 Oncol 67 Immune Mediated 67 Stent Implantation 67 Abstract Number 67 Neurosurg 67 R lenalidomide 67 Sapacitabine 67 Visceral Fat 67 Recurrent Breast Cancer 67 Autoimmune Diseases 67 Abstract Accepted 67 Pivotal Phase II 67 Chemotherapeutic Agents 67 PEGylated Fab fragment 67 Clinical Trial Enrollment 67 Radiofrequency Ablation 67 Intravitreal 67 Aliskiren 67 Small Molecule 67 Teva Provides Update 67 Carotid Stenting 67 J Pediatr 67 Dendritic Cells 67 Soft Tissue Sarcoma 67 Efficacy Trial 67 Induction Therapy 67 Thrombotic 67 Treat Anemia 67 Emerging Therapies 67 BiTE Antibody 67 Arterial Disease 67 REMINDER ORLive Presents 67 Potent Antiviral Activity 67 Aortic Stenosis 67 Significantly Improved 67 Cardiovascular Outcomes 67 orally administered inhibitor 67 Demonstrates Statistically Significant 67 Limb Ischemia 67 SYN# 67 Venous Thromboembolism 67 Proteasome 67 Combo Therapy 67 Pafuramidine 67 Acute Heart Failure 67 pan HDAC inhibitor 67 Receptor Antagonists 66 Interferon Alfa 66 Valopicitabine 66 Mylan Receives Approval 66 Survival Benefit 66 VASCULAR 66 Insulin Resistance 66 Phase Ib II 66 Liposomal 66 Cytochrome P# 66 Localized Prostate Cancer 66 Clin Pharmacol Ther 66 doi #.#/fj.#-# 66 Drug Shows Promise 66 Prostate Cancer Patients 66 Expanded Indication 66 Kinase Inhibitors 66 Slows Progression 66 Hernia Repair 66 Aneurysm Repair 66 Bazedoxifene 66 Myocardial Ischemia 66 Effectively Treats 66 Phospholipase A2 66 Vicriviroc 66 ABLYNX 66 polycythemia vera essential thrombocythemia 66 Cholesterol Lowering Drug 66 Diabetic Patients 66 Cell Lymphoma 66 dual endothelin receptor antagonist 66 Novel Therapies 66 AEGR 66 Well Tolerated 66 Vitro Activity 66 Heart Transplant Recipients 66 Newly Diagnosed Patients 66 Panzem R 66 Statistically Significant 66 Regenerative Cells 66 Genes Predict 66 Xyfid TM 66 Lung Injury 66 Cannabinoid 66 Trandolapril 66 Varespladib 66 Surgical Mesh 66 Hepatocellular Carcinoma 66 Artery Disease 66 Degarelix 66 Anticancer Compound 66 Study Validates 66 HCV Genotype 66 Platinol ® 66 Otelixizumab 66 Pediatric Patients 66 Endovascular Repair 66 Biol Phys 66 Unresectable 66 Gene Variants 66 Recombinant Human 66 Phase Ib clinical 66 Eur Arch 66 See WARNINGS 66 Cardiopulmonary Bypass 66 THERAPEUTICS INC. 66 samarium Sm 66 TRANSDUR ™ 66 Alvine Pharmaceuticals 66 Adenoma 66 Lung Cancers 66 Ovitrelle R Serostim 66 essential thrombocythemia ET 66 Platelet Inhibition 66 Hematological Cancers 66 Showed Significant 66 non nucleoside inhibitor 66 FDA Clears 66 Initiates Clinical Trials 66 Multiple Myeloma Patients 66 Sleep Disturbances 66 Clinical Efficacy 66 Gastrointestinal Stromal Tumors 66 pralatrexate injection folate analogue 66 Pharmacodynamic 66 RNAi Therapeutics 66 Factor Receptor 66 Oral Spray 66 Adult Stem Cell Therapy 66 RhuDex 66 Microwave Ablation System 66 Chronic Sinusitis 66 suppl #S 66 Abciximab 66 Adjuvant Therapy 66 STENT 66 Investigator Initiated 66 Receives Orphan Drug 66 Prostate Cancer Vaccine 66 PEGylated interferon beta 1a 66 Peripheral Blood 66 Treatment Naive Patients 66 Chronic Myeloid Leukemia 66 Surgical Treatment 66 Contrast Agent 66 Test Detects 66 Female Urology 66 PHARMACEUTICALS INC 66 Parenteral Nutrition 66 Gets FDA Clearance 66 Bipolar Depression 66 Lowers Risk 66 Oral Cladribine 66 Cyclooxygenase 2 66 Efficacy Results 66 Cancer Biomarkers 66 novel VDA molecule 66 Antithrombin 66 Resubmission 66 Reports Preclinical Data 66 Rheumatoid Arthritis Drug 66 FDA Okays 66 Reduced Risk 66 Initiates Phase 66 Novel Small Molecule 66 Novel Antibody 66 Inflammatory Diseases 66 Phase III Pivotal Trial 66 Hepatic Encephalopathy 66 Diagnostic Tests 66 Announces FDA Clearance 66 Zenvia Phase III 66 Study Showed 66 Advanced Solid Tumors 66 Tigecycline 66 CYP#A# CYP#D# 66 Cardiometabolic 66 Nat Genet 66 Anesth 66 Faropenem 66 Therapeutic Competitors Report 66 Complete Remission 66 Advanced Prostate Cancer 66 Acute Myocardial 66 Nuclear Receptors 66 Romidepsin 66 Statin Therapy 66 Treatment Experienced 66 Mg Uk 66 Kidney Function 66 Abstract Full Text 66 J Am Acad 66 Renal Anemia 66 VIVITROL ® 66 SPRYCEL ® 66 Node Positive 66 Romiplostim 66 Randomized Phase III 66 Tyrosine Kinase Inhibitors 66 Oral Presentations 66 Molecular Basis 66 refractory chronic lymphocytic 66 Proves Effective 66 Predict Response 66 Rheumatoid 66 Breast Cancer Recurrence 66 Monotherapy 66 Antitumor 66 Am J Clin 66 Metastatic Colorectal Cancer 66 Cardiac Resynchronization 66 #:#-# [025] 66 Fast Track Status 66 Osteoporosis Drug 66 SinuNase TM 66 HuMax 66 Free Full Text 66 Beta Amyloid 66 Advanced Pancreatic Cancer 66 Ischemic Stroke 66 Universal Flu Vaccine 66 Coronary Arteries 66 Less Invasive 66 MKC# MKC# PP 66 Improved Survival 66 sunitinib Sutent ® 66 Hemorrhagic Stroke 66 brivaracetam 65 Synthetic Peptide 65 J Consult Clin 65 Patients Enrolled 65 Annu Rev 65 Polymorphisms 65 alpha 2a 65 Receptor Antagonist 65 CYT# potent vascular disrupting 65 Oral Presentation 65 Announcement acc 65 FDA Accepts 65 ACE Inhibitors 65 Transdermal Patch 65 Diabetic Macular Edema 65 humanized interleukin 6 65 Chemotherapy Induced 65 Fast Skeletal Troponin 65 Respiratory Virus 65 PROSTASCINT R 65 Milestone Payments 65 Aggressive Reduction 65 Modulates 65 Septic Shock 65 Naive Patients 65 Phase 2a Study 65 Poniard Pharmaceuticals Announces 65 highly selective inhibitor 65 Autoimmune Disease 65 Oral Cavity 65 ST Elevation Myocardial 65 J Natl Cancer Inst 65 Ophthalmol 65 Preclinical Studies 65 EnteroMedics proprietary neuroblocking technology 65 LibiGel ® 65 Refractory Hodgkin Lymphoma 65 Receives Fast Track 65 PANVAC VF 65 Presents Preclinical 65 MKC# MT 65 Patency 65 Unstable Angina 65 Ancrod 65 MR Angiography 65 Upcoming Milestones 65 Nat Rev 65 Myocet 65 Dermatol 65 Patient Treated 65 Follicular Lymphoma 65 chronic eosinophilic leukemia 65 Demonstrates Potential 65 Rotavirus Vaccine 65 Fallopian Tube 65 STRIDE PD 65 Intracranial Aneurysms 65 Oral Insulin 65 CTAP# Capsules 65 MEND CABG 65 CARDIOVASCULAR 65 Helps Predict 65 Signaling Pathway 65 Infect Dis 65 Combination Clinical Trial 65 Randomised Controlled Trial 65 CB2 selective receptor agonist 65 Epidermal Growth Factor Receptor 65 Overactive Bladder 65 2 inhibitor CYT# 65 Nuvelo Announces 65 Fondaparinux 65 Ischemic 65 Clinical Trials Update 65 Intravascular 65 Carotid Endarterectomy 65 Intravenous Formulation 65 Tipranavir 65 Catheter Associated 65 Dose Response 65 Clinical Study Shows 65 histone deacetylase HDAC inhibitor 65 ARRY # 65 Hematologic Malignancies 65 2 methoxyestradiol 65 J Clin Endocrinol Metab 65 Tiotropium 65 Randomized Phase II 65 Kidney Int 65 Androgen Receptor 65 Anti CD# Antibody 65 Disease Progression 65 Chronic Liver Disease 65 Intravenous Immunoglobulin 65 Levels Linked 65 Demonstrates Ability 65 SABCS 65 Lymphocytic 65 Circulating Tumor Cells 65 Sustained Efficacy 65 Adverse Event 65 Renal Artery 65 Liver Tumors 65 Psychopharmacol 65 Neoadjuvant 65 Smooth Muscle 65 Hyperlipidemia 65 Hedgehog Pathway Inhibitor 65 huN# DM1 65 Stent Placement 65 LENALIDOMIDE 65 Acute Coronary Syndromes 65 FDA Approvable Letter 65 FOLOTYN ® 65 Tumor Angiogenesis 65 Blinatumomab 65 Stent Thrombosis 65 Tumor Response 65 Biologic Therapy 65 Microalbuminuria 65 Nephrol Dial Transplant 65 Inhaled Nitric Oxide 65 sunitinib Sutent 65 Adenomas 65 Protein Involved 65 Liver Failure 65 AnaSpec Introduces 65 Male Contraceptive 65 Decitabine 65 Anti Inflammatory Drug 65 Chronic Bronchitis 65 Acute Treatment 65 Combination Therapy 65 Pneumococcal Vaccine 65 Ecallantide 65 Fracture Risk 65 Inhibits 65 Small Bowel 65 Tumor Growth 65 REG2 65 Depressive Symptoms 65 Transplant Patients 65 Dry Powder Inhalers 65 Phase IIA 65 Malignant Melanoma 65 Retreatment 65 Oral Insulin Capsule 65 topically administered 65 Clin Orthop 65 Aortic Dissection 65 candesartan cilexetil 65 Versus Placebo 65 Protein Synthesis 65 Tablet Formulation 65 Ann Rheum Dis 65 Drug Formulation 65 Decompensated Heart Failure 65 Relapsed Multiple Myeloma 65 NABTT 65 #:# -# [003] 65 Bortezomib 65 Environ Health Perspect 65 #:# -# [005] 65 Seasonal Influenza Vaccine 65 Am J Epidemiol 65 Asthma Treatment 65 Nucleic Acids Res 65 CLINICAL PHARMACOLOGY 65 evaluating tivozanib 65 Solid Tumors 65 Key Milestones 65 ZYBRESTAT TM 65 Postdoctoral Position 65 oral prodrug 65 VioQuest oncology portfolio 65 ONCOLOGY 65 Low Dose 65 Fulvestrant 65 Endovascular Treatment 65 Parathyroid 65 Presents Positive Preclinical 65 targeted radiotherapeutic 65 Chronic Lymphocytic Leukemia CLL 65 Reduces Risk 65 Pharmacologic 65 Non Alcoholic Fatty 65 Immune Responses 65 Receives Milestone Payment 65 BIOSCIENCES 65 Uterine Fibroid Embolization 65 TLK# 65 Vaccine Adjuvants 65 Metabolic Disease 65 Ann Oncol 65 Pyridorin TM 65 Macrophage 65 Oral Laquinimod 65 R Saizen R 65 Osteoarthritis Patients 65 Stent Coating 65 GOUT 65 J Shoulder Elbow 65 Archexin 65 metastatic castration resistant 65 PRN FDA Approves 65 Total Knee Arthroplasty 65 epoetin alpha 65 Therapeutic Antibodies 65 treatment naive genotype 65 Preclinical Efficacy 65 Drug Fails 65 Sandostatin R 65 DUROS 65 Aeolus Pharmaceuticals Announces 65 Arch Otolaryngol Head 65 Therapeutic Efficacy 65 Atypical Hemolytic Uremic Syndrome 65 Prodrug 65 Cardiac Function 65 Rigel R# 65 Immunosuppression 65 Desvenlafaxine Succinate 65 J Allergy Clin 65 5q MDS 65 Myeloma Patients 65 catheter occlusion 65 Breast Carcinoma 65 Cannabinor 65 Induction Chemotherapy 65 Largest Database 65 Fetal Neonatal Ed 65 Antiplatelet Therapy 65 Gene Linked 65 mertansine 65 Liver Metastases 65 Reduces Mortality 65 Irbesartan 65 Susceptibility Testing 65 Carcinomas 65 Patient Outcomes 65 REPORTS THIRD QUARTER 65 Phase IIB 65 Multicenter Study 65 Cell Transplants 65 B Cell Lymphoma 65 Risk Stratification 65 Invasive Fungal Infections 64 Advanced Colorectal Cancer 64 unfractionated heparin UFH 64 PNP inhibitor 64 Tumor Suppressor Gene 64 Renal Impairment 64 Heart Circ Physiol 64 Vaccine Candidate 64 Beneficial Effects 64 ACTEMRA TM 64 Chronic Renal Failure 64 PROTEGE 64 Malignancies 64 Muscle Wasting 64 Kidney Transplant Recipients 64 abacavir sulfate lamivudine 64 Cancer Vaccines 64 CLL SLL 64 Low Incidence 64 Lenalidomide 64 Retinal Vein Occlusion 64 Thiazolidinediones 64 J Virol 64 Safety Tolerability 64 INSPIRE Trial Phase III 64 Diagnostic Criteria 64 EMBO J. 64 Melphalan 64 TNF Tumor Necrosis Factor 64 Enzyme Replacement Therapy 64 Intervention Effectiveness 64 XPEL Announces 64 sarcoma melanoma 64 PF # [002] 64 Blood Cancers 64 Radical Prostatectomy 64 Reduces Pain 64 Phase III PREGNANT PROCHIEVE 64 Cypher Sirolimus 64 Denufosol 64 Hematologic 64 Partial Nephrectomy 64 SinuNase ™ 64 Unfractionated Heparin 64 Int J 64 FEMALES SHOULD BE ADVISED 64 Epilepsy Drug 64 phase IIa clinical 64 Menstrual Pain 64 Iloperidone 64 Breast Brachytherapy 64 Cognitive Deficits 64 Radiation Treatment 64 Contrast Enhanced 64 Heterozygous Familial Hypercholesterolemia 64 cell lymphoma CTCL 64 Milestone Payment From 64 Synta Announces 64 Isavuconazole 64 ATAC Arimidex Tamoxifen Alone 64 Invasive Breast Cancer 64 Postmenopausal Women 64 Diabetic Macular Edema DME 64 Nilotinib 64 Phase 2a clinical trials 64 Breast Ultrasound 64 MOTOGP +#.# [001] 64 NASH Huntington 64 Rheumatol 64 Bivalirudin 64 Hypercholesterolemia 64 Benign Prostatic Hyperplasia 64 Lymphoma Patients 64 Angiogenic 64 Anti Inflammatory 64 Topical Treatment 64 Calcium Acetate 64 HER2 Positive Breast Cancer 64 Receive Milestone Payment 64 Epratuzumab 64 Sunesis Pharma 64 Chronic Lymphocytic Leukemia 64 Leukemias 64 Muscle Cells 64 Cardiovascular Mortality 64 Reperfusion Injury 64 Gynecol Oncol 64 Cardiomyocytes 64 Dasatinib 64 Phase IIIb 64 Arch Facial Plast 64 Vaccine Protects Against 64 Bronchiectasis 64 5 Fluorouracil 64 Omacetaxine 64 Delipidation 64 somatostatin analog 64 Syncria R 64 Am Soc Nephrol 64 Vertebral Fracture 64 Aplidin R 64 Adjunctive 64 HCV SPRINT 64 Phase IIa Trial 64 Announces Poster Presentations